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Abstract 
Chronic kidney disease (CKD) is a worldwide public health problem with an increasing incidence, poor 
outcomes and high cost. Patients with CKD suffer from a progressive loss of glomerular filtration. The kidneys 
lose the capacity to remove potentially toxic compounds from the blood stream into the urine, resulting in their 
accumulation in the body. The accumulation of these toxins has a negative impact on many body functions. 
Consequently, CKD is a complex disease that often affects multiple organ systems and coexists with numerous 
associated conditions of which cardiovascular disease is a highly important one. Unfortunately, CKD is usually 
detected in one of its later stages. In the search for CKD biomarkers we developed a serum based GC-MS 
platform. A derivatization method using oximation and silylation was optimized and applied to extracts 
originating from 49 patients in the different CKD stages and 10 healthy controls. The resulting data were treated 
with XCMS followed by multivariate statistical analysis and metaXCMS. Differentiation was achieved between 
the metabolic profile of the CKD patients and controls. The biomarker candidates have to be investigated and 
confirmed in prospective studies. 
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